IL-22, a vital cytokine in autoimmune diseases
Clinical and Experimental Immunology · 12.11.2024 · 218 (3) · 242-263
DOI: 10.1093/cei/uxae035 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Clinical and Experimental Immunology, online erschienen am 23.04.2024. Verfasst von Jiajin Li und 9 weiteren Autor:innen. Beteiligte Einrichtung: The Second Clinical School of Medicine, Anhui Medical University, Hefei, China. Hauptthemen laut MEDLINE: Interleukins, Interleukin-22, Autoimmune Diseases, Signal Transduction. Die Arbeit wurde bisher 21-mal zitiert (Crossref) und nennt 267 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: National Natural Science Foundation of China, Anhui Science Fund for Distinguished Young Scholars, Research Improvement Program of Anhui Medical University.
Abstract (Originalsprache)
Interleukin-22 (IL-22) is a vital cytokine that is dysregulated in various autoimmune conditions including rheumatoid arthritis (RA), multiple sclerosis (MS), and Alzheimer’s disease (AD). As the starting point for the activation of numerous signaling pathways, IL-22 plays an important role in the initiation and development of autoimmune diseases. Specifically, imbalances in IL-22 signaling can interfere with other signaling pathways, causing cross-regulation of target genes which ultimately leads to the development of immune disorders. This review delineates the various connections between the IL-22 signaling pathway and autoimmune disease, focusing on the latest understanding of the cellular sources of IL-22 and its effects on various cell types. We further explore progress with pharmacological interventions related to targeting IL-22, describing how such therapeutic strategies promise to usher in a new era in the treatment of autoimmune disease.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- The Second Clinical School of Medicine, Anhui Medical University, Hefei, China.
- The First Clinical School of Medicine, Anhui Medical University, Hefei, China.
- The School of pharmacy, Anhui Medical University, Hefei, China.
- The School of Basic Medical Sciences, Anhui Medical University, Hefei, China.
ORCID-Profile: Hu Wanglai
Förderung
- National Natural Science Foundation of China
- Anhui Science Fund for Distinguished Young Scholars
- Research Improvement Program of Anhui Medical University
Zitieren
APA
Li, J., Wu, Z., Wu, Y., Hu, X., Yang, J., Zhu, D., Wu, M., Li, X., Bentum-Ennin, L., & Wanglai, H. (2024). IL-22, a vital cytokine in autoimmune diseases. Clinical and Experimental Immunology, 218(3), 242-263. https://doi.org/10.1093/cei/uxae035
Vancouver
Li J, Wu Z, Wu Y, Hu X, Yang J, Zhu D, et al. IL-22, a vital cytokine in autoimmune diseases. Clinical and Experimental Immunology. 2024;218(3):242-263. doi:10.1093/cei/uxae035
BibTeX
@article{Li2024,
author = {Li, Jiajin and Wu, Zhen and Wu, Yuxin and Hu, XinYu and Yang, Jun and Zhu, Dacheng and Wu, Mingyue and Li, Xin and Bentum-Ennin, Lutterodt and Wanglai, Hu},
title = {IL-22, a vital cytokine in autoimmune diseases},
journal = {Clinical and Experimental Immunology},
year = {2024},
volume = {218},
number = {3},
pages = {242--263},
doi = {10.1093/cei/uxae035}
}
EUVIMED